Glucose Monitoring to Spot Early Loss of Islet Graft Function in Type 1 Diabetes
Studies whether glucose sensor readings signal early graft decline in adults with type 1 diabetes.
Plain-language title generated from the registry record
Registry title: Study of Glucose Tolerance Abnormalities Using Continuous Glucose Monitoring for the Identification of Early Loss of Pancreatic Islet Graft Function.
Key facts
- Where
- Strasbourg, FranceSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with insulin-dependent diabetes who have finished a full cycle of pancreatic islet transplantation. It studies a glucose monitor reading to see if it shows early loss of graft function.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- Insulin-dependent diabetes (type 1 diabetes, or diabetes caused by chronic pancreatitis, MODY or cystic fibrosis) after a full cycle of islet transplantation.
- Earlier treatment
- Must have had a full cycle of pancreatic islet transplantation: islet transplantation alone, islet after kidney, or simultaneous islet kidney. Needs more than 10,000 IEQ/kg of body weight, or less than 10,000 IEQ/kg with insulin independence achieved.
Main reasons for not taking part
- Refuses to wear a continuous glucose monitoring device
- Had a pancreatic islet autotransplantation
- Cannot give informed consent
- Is under judicial protection
- Is under guardianship or curatorship
Read by machine on 12 November 2026.
Where in France
- Hopitaux Universitaires de StrasbourgStrasbourg, FranceContact: Luc RAKOTOARISOATaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- University Hospital, Strasbourg, France
- Trial code
- NCT07470593
- Record updated
- 17 March 2026
- Original description
Islet transplantation is associated with drastically improvement glucose control in people with type 1 diabetes. This treatment resulted in the disappearance of severe hypoglycemic events. However, its long-term effectiveness is limited by progressive loss of graft function. Currently, there is no standardized method to detect early dysfunction of the transplanted islets.Read full original descriptionShow less
Prospective Longitudinal Observational Study of Glucose Tolerance Abnormalities Using Continuous Glucose Monitoring for the Identification of Early Loss of Pancreatic Islet Graft Function.
Islet transplantation is associated with drastically improvement glucose control in people with type 1 diabetes. This treatment resulted in the disappearance of severe hypoglycemic events. However, its long-term effectiveness is limited by progressive loss of graft function. Currently, there is no standardized method to detect early dysfunction of the transplanted islets.
This study aims to determine whether a parameter derived from continuous glucose monitoring (CGM), Time in Tight Range (70-140 mg/dL), is associated with pancreatic islet grafts function.
The study hypothesis is that a decrease in Time in Tight Range reflects early loss of islet graft function.
Inclusion: ≥18 years old; Insulin-dependent diabetes (type 1 diabetes, secondary to chronic pancreatitis, MODY, cystic fibrosis); Patient who has completed a full cycle of pancreatic islet transplantation, either:; Islet Transplantation Alone (ITA), or; Islet After Kidney (IAK), or; Simultaneous Islet Kidney (SIK), with >10,000 IEQ/kg of recipient body weight, or <10,000 IEQ/kg but having achieved insulin independence; Patient who has provided consent for reuse of their data for this research.
Exclusion: Patient refusal to wear continuous glucose monitoring device; Pancreatic islet autotransplantation; Inability to provide informed consent (e.g., difficulties understanding study information); Patient under judicial protection (safeguard of justice); Patient under guardianship or curatorship.